Spero

ROSEN, A LEADING LAW FIRM, Encourages Spero Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO

Retrieved on: 
Sunday, June 12, 2022
Titan, New Drug Application, Facebook, THE, Food, LinkedIn, Court, Class, Workforce, Pyelonephritis, FDA, GLOBE, WHY, Urinary tract infection, Spero, Food and Drug Administration, NASDAQ, Advertising, Twitter, Tebipenem, Lists of schools in England, NDA, I-Space (Chinese company), TO, Medical device, Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SPRO Investor Update: Robbins LLP Reminds Shareholders Lead Plaintiff Deadline in Class Action Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Saturday, June 11, 2022
Steps, Company, HBR, Securities Exchange Act of 1934, Infection, Food, News, MDR, Failure, Workforce, Therapy, FDA, GLOBE, Patient, Urinary tract infection, Review, Spero, NASDAQ, SAN, LCM, Population, NDA, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Person, Pharmaceutical industry, Generic drug, Tebipenem

Spero is clinical-stage biopharmaceutical company that focuses on developing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

Key Points: 
  • Spero is clinical-stage biopharmaceutical company that focuses on developing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections.
  • If you would like more information about Spero Therapeutics, Inc.'s misconduct, click here .
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Thursday, June 9, 2022
Legal, Professional Services, New Drug Application, Time, Company, HBR, Food, Court, News, Workforce, Therapy, FDA, Defendant, Review, GPM, NASDAQ, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Medical device, Pharmaceutical industry, Spero

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).

Key Points: 
  • Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO ) securities between October 28, 2021 and May 2, 2022, inclusive (the Class Period).
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Moore Kuehn, PLLC Encourages Investors of OKTA and SPRO to Contact Law Firm

Retrieved on: 
Thursday, June 9, 2022
Tebipenem, PLLC, FDA, OKTA, GLOBE, NDA, Company, Wall Street, Telephone, Advertising, Workforce, Okta, Spero

If you own OKTA or SPRO please contactJustin Kuehn, Esq.by email at [email protected] or telephone at (212) 709-8245.

Key Points: 
  • If you own OKTA or SPRO please contactJustin Kuehn, Esq.by email at [email protected] or telephone at (212) 709-8245.
  • There is no cost to you.
  • Moore Kuehn is aNew York-based law firm with attorneys representing investors and consumers.
  • Prior results do not guarantee similar outcomes.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Wednesday, June 8, 2022
Legal, Professional Services, New Drug Application, Time, Company, HBR, Food, Court, News, Telephone, Workforce, Therapy, FDA, Defendant, Review, NASDAQ, Law, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Security (finance), Pharmaceutical industry, Spero

Investors suffering losses on their Spero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Spero investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors

Retrieved on: 
Tuesday, June 7, 2022
Legal, Professional Services, New Drug Application, Time, Company, HBR, Food, Court, News, Workforce, Therapy, FDA, Defendant, Review, GPM, NASDAQ, Tebipenem, Urinary tract infection, Lists of schools in England, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Suite, Medical device, Pharmaceutical industry, Spero

Spero investors have until July 25, 2022 to file a lead plaintiff motion.

Key Points: 
  • Spero investors have until July 25, 2022 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

HARMONIC BIONICS ENTERS INTO STRATEGIC PARTNERSHIP WITH CUREXO INC. AND COMPLETES FIRST US INSTALLATION OF END-EFFECTOR ROBOTIC GAIT REHAB DEVICE, MORNING WALK S200

Retrieved on: 
Tuesday, June 7, 2022
Exercise, Life, Lists of diseases, Knee, Stroke, Bionics, Human, Hip, CIPD, Partnership, Virtual reality, Multimedia, Morning Walk, FDA, Robotics, Patient, Hospital, Technology, Spero, Movement, Rehabilitation, Chronic inflammatory demyelinating polyneuropathy, Ascending limb of loop of Henle, View, Medical device, 3D printing

Harmonic Bionics will assist with US promotion and business development for Curexo's Morning Walk S200 , a robotic gait rehabilitation system, and CUVIS-spine , a surgical spine robot.

Key Points: 
  • Harmonic Bionics will assist with US promotion and business development for Curexo's Morning Walk S200 , a robotic gait rehabilitation system, and CUVIS-spine , a surgical spine robot.
  • Harmonic Bionics announces a $3 million investment from South Korea-based medical robot manufacturer Curexo, Inc.
  • Effective immediately, Harmonic Bionics will be responsible for managing the first US installation of Morning Walk S200, an FDA-registered robotic gait rehabilitation system, at Spero Rehab Clinic in Austin, TX.
  • "We are excited that patients and therapists are seeing a real benefit from using Morning Walk S200 for gait training," said Harmonic Bionics CEO Christopher Prentice.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO

Retrieved on: 
Sunday, June 5, 2022
Titan, New Drug Application, Facebook, THE, Food, LinkedIn, Court, Class, Workforce, Pyelonephritis, FDA, GLOBE, WHY, Urinary tract infection, Spero, Food and Drug Administration, NASDAQ, Advertising, Twitter, Tebipenem, Lists of schools in England, NDA, I-Space (Chinese company), TO, Tobacco, Insurance

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Twitter, LMP, and Spero and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, June 4, 2022
New Drug Application, Mission statement, Company, HBR, Ownership, Infection, Food, Annual report, Income, Complicated, News, Treatment, Lists of schools in England, Workforce, FDA, GLOBE, Patient, Defendant, TWTR, Review, Musk, Spero, NYSE, Urinary tract infection, Tebipenem, NASDAQ, SEC, Population, LMP, NDA, Degenerative disease, U.S. Securities and Exchange Commission, Disclosure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Documentation, Relevant, Complaint, Cryptocurrency, Audit, Medical device, Renewable energy, Pharmaceutical industry, Forbes, Twitter, Pyelonephritis, P.C

By failing to timely disclose his ownership stake, Musk was able to acquire shares of Twitter less expensively during the Class Period.

Key Points: 
  • By failing to timely disclose his ownership stake, Musk was able to acquire shares of Twitter less expensively during the Class Period.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • For more information on the Spero class action go to: https://bespc.com/cases/SPRO
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Spero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Retrieved on: 
Thursday, June 2, 2022
Tebipenem, FDA, Lists of schools in England, GLOBE, NDA, Company, Review, Workforce, NASDAQ, Pharmaceutical industry, Spero

LOS ANGELES, June 02, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors.

Key Points: 
  • LOS ANGELES, June 02, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors.
  • Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.